Trial reportZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2017
[Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
Open access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.Hepatology international · 2020Trial
- [Expert recommendations on the management of adverse reactions in pegylated interferon alpha therapy for chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Yushida: an IoT-based smart injection system for long-term management of chronic diseases.Frontiers in digital health · 2026Review
- Safety evaluation and toxicokinetics of repeated inhalation exposure to pegylated interferon α-2b.Frontiers in pharmacology · 2025Article
- A genetic variant ofJournal of clinical microbiology · 2024Article
- CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients.Journal of clinical and translational hepatology · 2023Article
- Guidelines for Prevention and Treatment of Chronic Hepatitis B.Journal of clinical and translational hepatology · 2021Article
- A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B.Pharmacogenomics and personalized medicine · 2021Article
- Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels.Open forum infectious diseases · 2020Article
- [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 20 institutions in 1 country.
F Q HouDepartment of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China.
Y L YinXiamen Amoytop Biotech Co., Ltd, Xiamen 361028, China.
L Y ZengXiamen Amoytop Biotech Co., Ltd, Xiamen 361028, China.
J ShangHenan Provincial People's Hospital, Zhengzhou 450003, China.
G Z GongThe Second Xiangya Hospital of Central South University, Changsha 410011, China.
C PanFuzhou Infectious Disease Hospital, Fuzhou 350025, China.
M X ZhangThe Sixth People's Hospital of Shenyang, Shenyang 110006, China.
C B YinGuangzhou Eighth People's Hospital, Guangzhou 510060, China.
Q XieRuijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Y Z PengPeking University Shenzhen Hospital, Shenzhen 518036, China.
S J ChenJinan Infectious Disease Hospital, Jinan 250021, China.
Q MaoSoutheast Hospital, Third Military Medical University, Chongqing 400038, China.
Y P ChenThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Q G MaoXiamen Hospital of T.C.M, Xiamen 361001, China.
D Z ZhangThe Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
T HanTianjin Third Central Hospital, Tianjin 300170, China.
M R Wang81th Hospital of People's Liberation Army, Nanjing 210002, China.
W ZhaoThe Second Affiliated Hospital of the Southeast University, Nanjing 210003, China.
J J LiuThe First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
Y HanXijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
L F ZhaoThe First Affiliated Hospital of Shanxi University, Taiyuan 030001, China.
G H LuoThe First Affiliated Hospital of Guangxi Medical Universtiy, Nanning 530021, China.
J M ZhangHuashan Hospital, Shanghai 200040, China.
J PengNangfang Hospital, Southern Medical University, Guangzhou 510510, China.
D M TanXiangya Hospital Central South University, Changsha 410008, China.
Z W LiShengjing Hospital of China Medical University, Shenyang 110022, China.
H TangWest China Hospital, Sichuan University, Chengdu 610041, China.
H WangPeking University People's Hospital, Beijing 100044, China.
Y X ZhangThe First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
J LiJiangsu Provincial People's Hospital, Nanjing 210029, China.
L L ZhangThe First Affiliated Hospital of Nanchang University, Nanchang 360102, China.
L ChenShanghai Public Health Clinical Center, Shanghai 201508, China.
J D JiaBeijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
C W Chen85th Hospital of People's Liberation Army, Shanghai 200052, China.
Z ZhenThe Third Affiliated Hospital of Hebei Medical University, Shijiazhuang 050051, China.
B S Li302 Military Hospital of China, Beijing 100039, China.
J Q NiuThe First Bethune Hospital of Jilin University, Chanchun 130062, China.
Q H MengBeijing Youan Hospital, Captial Medical University, Beijing 100069, China.
H YuanThe First Hospital of Lanzhou University, Lanzhou 730000, China.
Y T SunTangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.
S C LiThe 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
J F ShengThe First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
J ChengBeijing Ditan Hospital Capital Medical University, Beijing 100015, China.
L SunXiamen Amoytop Biotech Co., Ltd, Xiamen 361028, China.
G Q WangDepartment of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China.
302 Military Hospital of China · CNAir Force Medical University · CNBeijing Ditan Hospital · CNBeijing Friendship Hospital · CNCentral South University · CNChongqing Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNFirst Affiliated Hospital of Xiamen University · CNFirst Affiliated Hospital Zhejiang University · CNFirst Hospital of Lanzhou University · CNGuangzhou Eighth People's Hospital · CNHarbin Medical University · CNHenan Provincial People's Hospital · CNHuashan Hospital · CNJinan Infectious Disease Hospital · CNPeking University · CNPeking University First Hospital · CNPeking University People's Hospital · CNPeking University Shenzhen Hospital · CNSecond Xiangya Hospital of Central South University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antiviral AgentsDNA, ViralFemaleHepatitis B, ChronicHepatitis B e AntigensHepatitis B Surface AntigensHumansInjectionsInterferon-alphaPolyethylene GlycolsRecombinant ProteinsTreatment OutcomeAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsRecombinant ProteinsClinical trialHBeAg seroconversionHepatitis B, chronicPeginterferon
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.